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This paper explores a phenomenon of 
patent aggregators, entities that acquire 
third party patents with the goal of com-
mercializing them by means of sale, li-
censing, enforcement, or creation of new 
patent-based companies. Based on the 
existing literature, we provide a clas-
sification of distinctive types of patent 
aggregators. Using several qualitative re-
search methods, we construct a compre-
hensive mapping of patent aggregators 
established in Europe. By means of four 
case studies, we illustrate various char-
acteristics of patent aggregator business 
models and their strategies. Finally, we 
identify main barriers and key success 
factors for functioning of patent aggrega-
tors, leading to several policy and practi-
cal recommendations.
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Most of the studies on pharmaceutical in-
novation focus on the drug discovery and 
the R&D process. This paper looks at the 
story behind the attempt to revive ABACA-
VIR, a drug employed in the treatment of 
patients with HIV/AIDS since it was dis-
covered that hypersensitivity reactions 
to the drug were significantly associated 
with a genetic trait. The study is based 
on the historical method: through a series 
of interviews and secondary documen-
tation we have explored the network of 
Italian research centres sponsored by ViiV 
Healthcare and the competences brought 
in to play to develop a strategy to keep 
the compound on the market and assure 
patients’ safety. The historical recon-
struction shows that the `point of entry’ 
of pharmacogenetics into the mainstream 
pharmaceutical market was determined 
by the needs of the patent holder rath-
er than technology driven dynamics and 
subject to the availability of technologies, 
standardised guidelines and pharmacoge-
nomics-specific competences (Crews et 
al, 2012). In this pursuit, the patent hold-
er has been targeting the integration of 
pharmaceuticals core-activities either in 
pharmaceutical science and/or research 
and development and benefitting from 
connecting with the science base outside 
the pharmaceutical industry involving 
university virology and pharmacology lab-
oratories, clinical and diagnostic centres. 
The participants to the Italian network 
seem to self-organise around themes set 
out together with ViiV Healthcare and on 
the basis of the personal competences, 
capabilities and capacity of the individu-
als. The organisation does not fully reflect 
current collaborative management prac-
tices such as open innovation or other 
contractual collaborative R&D arrange-
ments (i.e R&D outsourcing).
